



August 24, 2023

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943
Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Proceedings of the Annual General Meeting - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We would like to inform that 47th Annual General Meeting of the members of the Company was held on Thursday, August 24, 2023 at 3.00 P.M. (IST) through Video Conference (VC)/ Other Audio Visual Means (OAVM) in accordance with the Companies Act, 2013, and the Rules made thereunder and the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with General Circular No. 10/2022 dated December 28, 2022, General Circular No. 20/2020 dated May 5, 2020, General Circular No. 14/2020 dated April 8, 2020 and General Circular No.17/2020 dated April 13, 2020, and other applicable circulars issued by the Ministry of Corporate Affairs and SEBI.

77 members were present in person through VC/OAVM.

Mr. Ranjit Shahani - Chairman was unable to attend the meeting due to his health condition and therefore Mr. Sumit Bose had chaired the meeting. As the quorum was present, Mr. Sumit Bose, Chairman of the meeting, called the meeting to order and commenced the proceedings. He stated that the meeting was held through VC/OAVM as permitted by MCA and SEBI, and the Company had taken all efforts feasible under the circumstances to enable the members to participate and vote on the resolutions placed before the members for approval. The Chairman thereafter addressed the members.

All Board members except Mr. Ranjit Shahani participated in the meeting and introduced themselves to the members.

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



The notice convening the meeting was already circulated to the members and the same was taken as read.

The Chairman then stated that (a) Standalone Financial Statement for the financial year 2022-23 (b) Consolidated Financial Statement for the financial year 2022-23 (c) Auditors' Report (d) Secretarial Audit Report (e) Secretarial Auditors' Certificate on ESOP Scheme were available for inspection during the meeting on the NSDL portal. The Chairman also informed that the members may send e-mail to Company's designated e-mail ID to receive link for inspection of Register of Contracts and Register of Directors & Key Managerial Personnel.

The Chairman then informed the members that the Statutory auditors' report did not contain any qualification, observation or comment. He also informed the members that the Secretarial audit report was unqualified and did not contain any qualification, observation or comment. Hence, the same were not required to be read at the meeting.

The Chairman thereafter invited the members to offer their comments/ seek clarifications on the businesses before the meeting. Several members thereafter asked questions on businesses before the meeting as well as accounts/operations of the Company. At the request of the Chairman, Mr. Nikhil Chopra – Chief Executive Officer and Whole-Time Director and Mr. Lakshay Kataria – Chief Financial Officer replied to the questions from the members at the meeting.

At the request of the Chairman, the Company Secretary briefly explained the nature, objective and the implication of the seven (7) ordinary resolutions as set out in the notice of the meeting dated May 24, 2023 placed before the members.

The Company Secretary further stated that the Company had provided remote e-voting facility for all seven items of businesses mentioned in the notice of the meeting and stated that the members who had not cast their votes through remote e-voting were requested to cast their votes through e-voting platform of NSDL. The members who had already cast their votes through remote e-voting were not eligible to vote at the meeting.

He also informed the members that the Board of Directors had appointed Mr. Ashish Bhatt, Practicing Company Secretary, as Scrutinizer, to scrutinize the votes cast through remote e-voting and through e-voting at the meeting in a fair and transparent manner.

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com



The members were informed that the result of e-voting along with remote e-voting will be declared on or before August 26, 2023 by placing the same on website of the Company.

The meeting was concluded at 4.48 p.m. and the e-voting facility was made available to the members for 15 minutes post conclusion of the meeting.

Please note that the results of the voting will be separately informed to the Exchange.

Thanking you,

For J. B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President-Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com

www.jbpharma.com